4D Molecular Therapeutics Inc (NAS:FDMT)
$ 25.15 0 (0%) Market Cap: 1.30 Bil Enterprise Value: 788.60 Mil PE Ratio: 0 PB Ratio: 2.14 GF Score: 57/100

4D Molecular Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 15, 2022 / 03:40PM GMT
Release Date Price: $5.9 (+1.20%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good morning, everyone, and thank you for joining us for day 3 of the Goldman Sachs Healthcare Conference. We're really pleased to have 4D Molecular Therapeutics. And with us, we have David Kirn, Co-Founder and President and CEO of the company.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

With that, David, to start here, the company has demonstrated early proof of concept for multiple assets, including a drug for Fabry disease and one in an eye disease XLRP. Can you share your outlook for the near term and highlight your key events investors should be focused on next?

David H. Kirn
4D Molecular Therapeutics, Inc. - Co-Founder, CEO, President & Director

Well, first of all, thanks for having us, Salveen.

And just by way of background for the AAV of genetic medicines company, we have 5 products in the clinic across 3 therapeutic areas, all of which leverage vectors that we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot